Soumya (Som) Banerjee
CEO and Co-founder
Juvion Life Sciences
Lausanne, Switzerland
34 profile visitsSpeaker
Using a novel platform and innovative research, we develop therapies to sustain mobility and delay sarcopenia with age.
My organisation
Age-related mobility decline and conditions like sarcopenia are often linked to the deterioration of neuron-muscle communication. Juvion Life Sciences (JLS), a spin-off from EPFL, has identified innovative biological mechanisms that preserve neuromuscular connections, maintaining the structure and function of motor circuitry. This breakthrough is pivotal, demonstrating for the first time that mobility decline can be mitigated.
Building on this expertise, Juvion integrates cutting-edge, sustainable, first-in-class discovery platforms to develop safe and effective therapeutics aimed at stabilizing the motor system and combating mobility loss. Their mission is to make these solutions accessible to all aging individuals, addressing a critical societal challenge as the global population continues to grow older.
Speaker sessions (1)
Tuesday, 10 December 2024
10:15 - 11:20
Pitch Sessions Healthtech
Location:Pitch Area 1Track:Pitch Session
Experience the forefront of healthtech innovation at EPFL Investor Day!